MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
1.270
-0.110
-7.97%
After Hours: 1.390 +0.12 +9.46% 16:18 12/17 EST
OPEN
1.405
PREV CLOSE
1.380
HIGH
1.405
LOW
1.133
VOLUME
2.81M
TURNOVER
--
52 WEEK HIGH
2.680
52 WEEK LOW
0.9999
MARKET CAP
232.87M
P/E (TTM)
-15.6984
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HRTX last week (1208-1212)?
Weekly Report · 2d ago
Weekly Report: what happened at HRTX last week (1201-1205)?
Weekly Report · 12/08 09:41
Roth Capital healthcare analyst holds an analyst/industry conference call
TipRanks · 12/05 19:40
Heron Therapeutics announces APONVIE inclusion in PONV guidelines
TipRanks · 12/04 13:20
Heron Therapeutics Includes APONVIE Injectable Emulsion In Guidelines For Postoperative Nausea, Vomiting
Benzinga · 12/04 13:17
HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)
Reuters · 12/04 13:16
Weekly Report: what happened at HRTX last week (1124-1128)?
Weekly Report · 12/01 09:39
Weekly Report: what happened at HRTX last week (1117-1121)?
Weekly Report · 11/24 09:42
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.